Interestingly, new specific pathway inhibitors, e.g. Bcl-2 or BCRi, with excellent response rates in refractory CLL affect pathways promoting growth of cancer cells under severe hypoxia. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.